ADVFN Logo ADVFN

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
22.261,64
-1,53%
S&P 500
5.567,79
-0,83%
Dow Jones
41.385,05
-1,26%
Euro vs US Dollar
1,0909
0,65%
Bitcoin
80.174,51
2,19%
Pepperstone
Advertisement
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Altamira Therapeutics Ltd (CYTO)

  7. Altamira Therapeutics Ltd (CYTO) News

CYTO

Altamira Therapeutics (CYTO)

Altamira Therapeutics Ltd
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:CYTO
DatumZeitQuelleÜberschriftSymbolFirma
10/03/202521h30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CYTOAltamira Therapeutics Ltd
20/12/202414h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CYTOAltamira Therapeutics Ltd
20/12/202414h00GlobeNewswire Inc.Altamira Therapeutics Announces Transition from NASDAQ to OTC MarketsNASDAQ:CYTOAltamira Therapeutics Ltd
04/10/202422h01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CYTOAltamira Therapeutics Ltd
04/10/202422h01GlobeNewswire Inc.Altamira Therapeutics Provides Update on Nasdaq ListingNASDAQ:CYTOAltamira Therapeutics Ltd
27/09/202415h01GlobeNewswire Inc.Altamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification for Bentrio Nasal SprayNASDAQ:CYTOAltamira Therapeutics Ltd
24/09/202414h15Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CYTOAltamira Therapeutics Ltd
24/09/202414h01GlobeNewswire Inc.Altamira Therapeutics Provides Business Update and First Half 2024 Financial ResultsNASDAQ:CYTOAltamira Therapeutics Ltd
20/09/202415h01GlobeNewswire Inc.Altamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 2024NASDAQ:CYTOAltamira Therapeutics Ltd
19/09/202422h17Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CYTOAltamira Therapeutics Ltd
19/09/202422h01GlobeNewswire Inc.Altamira Therapeutics Announces Closing of up to $12.0 Million Public OfferingNASDAQ:CYTOAltamira Therapeutics Ltd
18/09/202422h19Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:CYTOAltamira Therapeutics Ltd
18/09/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CYTOAltamira Therapeutics Ltd
17/09/202423h00GlobeNewswire Inc.Altamira Therapeutics Announces Pricing of up to $12.0 Million Public OfferingNASDAQ:CYTOAltamira Therapeutics Ltd
16/09/202419h55Edgar (US Regulatory)Form F-1/A - Registration statement for certain foreign private issuers: [Amend]NASDAQ:CYTOAltamira Therapeutics Ltd
16/09/202415h29Edgar (US Regulatory)Form F-1/A - Registration statement for certain foreign private issuers: [Amend]NASDAQ:CYTOAltamira Therapeutics Ltd
16/09/202414h30GlobeNewswire Inc.Altamira Therapeutics Announces Expansion of Bentrio License and Distribution Agreement with Nuance Pharma in East and South East AsiaNASDAQ:CYTOAltamira Therapeutics Ltd
03/09/202415h01GlobeNewswire Inc.Altamira Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference September 9-11NASDAQ:CYTOAltamira Therapeutics Ltd
23/08/202415h01GlobeNewswire Inc.Altamira Therapeutics Announces Extension of Bentrio Distribution Agreement with Pharma Nordic to Include Sweden and DenmarkNASDAQ:CYTOAltamira Therapeutics Ltd
22/08/202422h53Edgar (US Regulatory)Form F-1 - Registration statement for certain foreign private issuersNASDAQ:CYTOAltamira Therapeutics Ltd
16/08/202415h01GlobeNewswire Inc.Altamira Therapeutics Announces Confirmed Suitability of Bentrio for Athletes as Comprehensive Testing Shows Absence of Prohibited SubstancesNASDAQ:CYTOAltamira Therapeutics Ltd
12/08/202415h02GlobeNewswire Inc.Altamira Therapeutics Announces Significant Enhancement of Immune Checkpoint Inhibition Therapy in Combination with Zbtb46 mRNA Delivered with SemaPhore Nanoparticles in Animal Tumor ModelsNASDAQ:CYTOAltamira Therapeutics Ltd
19/07/202415h01GlobeNewswire Inc.Altamira Therapeutics Announces Publication of Preclinical Data Showing Successful Treatment of Abdominal Aortic Aneurysm with SOD2 mRNA Delivered by SemaPhore NanoparticlesNASDAQ:CYTOAltamira Therapeutics Ltd
15/07/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CYTOAltamira Therapeutics Ltd
08/07/202423h17Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:CYTOAltamira Therapeutics Ltd
20/06/202415h01GlobeNewswire Inc.Altamira Therapeutics Highlights Newly Published Review Article Supporting Use of Betahistine in Vertigo ManagementNASDAQ:CYTOAltamira Therapeutics Ltd
28/05/202416h31GlobeNewswire Inc.Altamira Therapeutics Provides Business UpdateNASDAQ:CYTOAltamira Therapeutics Ltd
23/05/202414h47GlobeNewswire Inc.Altamira Therapeutics Announces Dissemination of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis Through Social Media Channels of Top Allergy JournalNASDAQ:CYTOAltamira Therapeutics Ltd
16/05/202422h15Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CYTOAltamira Therapeutics Ltd
01/05/202414h47GlobeNewswire Inc.Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and InflammationNASDAQ:CYTOAltamira Therapeutics Ltd
 Showing the most relevant articles for your search:NASDAQ:CYTO

Kürzlich von Ihnen besucht

LSE
95VC
Sant Uk Grp 45a
NASDAQ
GPRE
Green Plains
DBI
DH6N
Short DAX X7 Price Return
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2025 ADVFN PLC - Alle Rechte vorbehalten

Werbung entfernen

Melden Sie sich für ein werbefreies Erlebnis an

Keine Werbung

Versuchen Sie es jetzt

Anzeigen behalten